CNM-AU8

Serial Number 88715145
Registration 6090326
700

Registration Progress

Application Filed
Dec 4, 2019
Under Examination
Approved for Publication
Apr 14, 2020
Published for Opposition
Apr 14, 2020
Registered
Jun 30, 2020

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-30)
Due: Jun 30, 2026 331 days

Trademark Image

CNM-AU8

Basic Information

Serial Number
88715145
Registration Number
6090326
Filing Date
December 4, 2019
Registration Date
June 30, 2020
Published for Opposition
April 14, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 30, 2020
Registration
Registered
Classes
005

Rights Holder

CLENE NANOMEDICINE, INC.

03
Address
Suite 325
3165 Millrock Drive
Salt Lake City, UT 84121

Ownership History

CLENE NANOMEDICINE, INC.

Original Applicant
03
Salt Lake City, UT

CLENE NANOMEDICINE, INC.

Owner at Publication
03
Salt Lake City, UT

CLENE NANOMEDICINE, INC.

Original Registrant
03
Salt Lake City, UT

Legal Representation

Attorney
Janet G Ricciuti

USPTO Deadlines

Next Deadline
331 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-30)
Due Date
June 30, 2026
Grace Period Ends
December 30, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

9 events
Date Code Type Description Documents
Jun 30, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jun 30, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 14, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 14, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 25, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 6, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 5, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 10, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 7, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Therapeutic pharmaceuticals for the treatment of remyelination, diseases of Multiple Sclerosis, ALS and Parkinson's disease
First Use Anywhere: May 16, 2019
First Use in Commerce: May 16, 2019

Additional Information

Pseudo Mark
CNM-AUGUST EIGHTH; CNM-AUGUST EIGHT

Classification

International Classes
005